Abstract
HIV-1 integration into cell genomes is a key step in the HIV-1 replicative cycle. We applied a gene therapy strategy designed to block HIV replication at this early stage. To do this, we used a single chain antibody (SFv) against the DNA-binding domain of HIV-1 integrase (IN). SV40-derived vectors were used for gene transfer to human T-lymphocytes because of their high transduction efficiency and durability of transgene expression. HIV-1 replication was measured by supernatant p24 antigen levels. Protection by the test vector, SV(Aw), compared with mock- and SV(HBS) transduced cells used as negative controls, was assessed during 3 successive rounds of HIV-1 NL4-3 challenge. HIV-1 infectious dose escalated from 400 infectious units (IU) to 4000 IU.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
